Organization (Hospital)
Northside Hospital
ClinicalTrials.gov lists Northside Hospital as lead sponsor of 27 trials. It has 81 active development programs and 21 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Northside Hospital: 27 lead-sponsored trials and 1 legal-entity registration.
Disease areas (50)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lymphoma | 9 |
| Myelodysplastic Syndromes | 9 |
| Lymphoma, Non-Hodgkin | 8 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 |
| Hodgkin Disease | 7 |
Showing 5 of 50 disease areas.
Trials by start year as sponsor or collaborator (17)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 3 |
| 2023 | 1 |
| 2022 | 1 |
| 2020 | 2 |
| 2019 | 1 |
| 2016 | 2 |
| 2015 | 2 |
| 2014 | 1 |
Showing 10 of 17 years.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (81)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| FLUDARABINE | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Phase 2 | 6 |
| CYCLOPHOSPHAMIDE | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Phase 2 | 5 |
| FLUDARABINE | Multiple Myeloma | Phase 2 | 4 |
| RITUXIMAB | Bronchiolitis | Phase 2 | 3 |
| CYCLOPHOSPHAMIDE | Multiple Myeloma | Phase 2 | 3 |
Showing 5 of 81 active programs.
Approved assets (21)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| FLUDARABINE | 10 |
| CYCLOPHOSPHAMIDE | 7 |
| TACROLIMUS | 5 |
| RITUXIMAB | 4 |
| Busulfan | 4 |
Showing 5 of 21 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 38% hit target (n=8) | 29% on time (n=7) |
Journals published in (80)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Blood | 72 |
| Bone marrow transplantation | 23 |
| Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation | 21 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 18 |
| The New England journal of medicine | 13 |
Showing 5 of 80 journals.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 7 |
Organization relationships (5)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Blood and Marrow Transplant Group of Georgia | Co sponsors trial with | 8 |
| AbbVie Inc. | Co sponsors trial with | 1 |
| Merck & Co., Inc., Rahway, NJ, USA (United States) | Co sponsors trial with | 1 |
| Millennium Engineering and Integration (United States) | Co sponsors trial with | 1 |
| Teva Pharmaceuticals USA | Co sponsors trial with | 1 |
Latest dated events (35)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-07-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-11-18 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-08-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 35 events.
CLIA clinical laboratory certificates (2)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| NORTHSIDE HOSPITAL INC | Certificate of waiver | Active |
| NORTHSIDE HOSPITAL, INC | Certificate of waiver | Active |
Biomarker capability evidence (50)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CD34 | Trial sponsor | Named in trial inclusion criteria |
| CD34 | Trial sponsor | Named in trial inclusion criteria |
| CR1 | Trial sponsor | Named in trial inclusion criteria |
| ELN | Trial sponsor | Named in trial inclusion criteria |
| HLA-A | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 50 evidence rows.
Biomarkers this organization publishes on (53)
Shown in this order: most publications first.
Showing 5 of 53 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.